702P + 767B

702P + 767B is an experimental combination of two modified U1 small nuclear RNA (snRNA) expression constructs designed to silence the expression of the human chorionic gonadotropin beta subunit (hCGβ). This therapeutic strategy employs U1 snRNA-mediated inhibition (U1i), where the 5' end of the U1 snRNA is engineered to be complementary to specific sequences within the 3' terminal exon of the target hCGβ pre-mRNA. The binding of these modified U1 snRNAs (specifically at positions 702 and 767 of the mRNA) interferes with the polyadenylation process, leading to the degradation of the transcript and a significant reduction in protein secretion. Research indicates that the dual targeting provided by the 702P and 767B combination effectively induces apoptosis and inhibits the proliferation of hCGβ-secreting cancer cells, such as cervical cancer cell lines.

Other names

U1 snRNA-mediated inhibition of hCG beta subunitU-1 snRNA-mediated inhibition of hCG beta subunitU 1 snRNA-mediated inhibition of hCG beta subunit